These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 5481776)

  • 61. Plasma DOPA and growth hormone in parkinsonism: oscillations in symptoms.
    Papavasiliou PS; McDowell FH; Wang YY; Rosal V; Miller ST
    Neurology; 1979 Feb; 29(2):194-200. PubMed ID: 571063
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Decreased arginine-induced HGH response during L-dopa therapy in parkinsonian patients.
    Johnson SE; Norman N; Sjaastad O
    Acta Endocrinol (Copenh); 1974 Dec; 77(4):686-90. PubMed ID: 4479702
    [No Abstract]   [Full Text] [Related]  

  • 63. Inhibitory effect of L-Dopa on GH release in acromegalic patients.
    Liuzzi A; Chiodini PG; Botalla L; Cremascoli G; Silvestrini F
    J Clin Endocrinol Metab; 1972 Dec; 35(6):941-3. PubMed ID: 4634493
    [No Abstract]   [Full Text] [Related]  

  • 64. DOPA and amino acid levels in plasma and cerebrospinal fluid of patients with Parkinson's disease before and during treatment with L-DOPA.
    Hare TA; Beasley BL; Chambers RA; Boehme DH; Vogel WH
    Clin Chim Acta; 1973 May; 45(3):273-80. PubMed ID: 4708057
    [No Abstract]   [Full Text] [Related]  

  • 65. Effect of chlorpromazine on serum growth-hormone concentration in man.
    Sherman L; Kim S; Benjamin F; Kolodny HD
    N Engl J Med; 1971 Jan; 284(2):72-4. PubMed ID: 5538637
    [No Abstract]   [Full Text] [Related]  

  • 66. L-DOPA suppression of thyrotropin-releasing hormone response in man.
    Spaulding SW; Burrow GN; Donabedian R; van Woert M
    J Clin Endocrinol Metab; 1972 Jul; 35(1):182-5. PubMed ID: 4624348
    [No Abstract]   [Full Text] [Related]  

  • 67. Growth hormone responses to L-dopa in depressed patients.
    Sachar EJ; Mushrush G; Perlow M; Weitzman ED; Sassin J
    Science; 1972 Dec; 178(4067):1304-5. PubMed ID: 4640070
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical and cerebrospinal fluid changes in parkinsonian patients treated with L-3,4-dihydroxyphenylalanine (L-dopa).
    Sharpless NS; Ericsson AD; McCann DS
    Neurology; 1971 May; 21(5):540-9. PubMed ID: 5104098
    [No Abstract]   [Full Text] [Related]  

  • 69. Metabolic responses to levodopa.
    N Engl J Med; 1972 Dec; 287(25):1302-3. PubMed ID: 4636900
    [No Abstract]   [Full Text] [Related]  

  • 70. Effect of L-dihydroxyphenylalanine upon serum growth hormone concentrations in children and adolescents.
    Root AW; Russ RD
    J Pediatr; 1972 Oct; 81(4):808-13. PubMed ID: 5074361
    [No Abstract]   [Full Text] [Related]  

  • 71. Inhibitory effect of dopaminergic stimulation on GH release in acromegaly.
    Chiodini PG; Liuzzi A; Botalla L; Cremascoli G; Silvestrini F
    J Clin Endocrinol Metab; 1974 Feb; 38(2):200-6. PubMed ID: 4812616
    [No Abstract]   [Full Text] [Related]  

  • 72. Letter: Enhancement of levodopa-induced growth-hormone stimulation by propranolol.
    Camanni F; Massara F
    Lancet; 1974 May; 1(7863):942. PubMed ID: 4133478
    [No Abstract]   [Full Text] [Related]  

  • 73. Effect of intravenous and oral administration of L-dopa on HGH and TSH release.
    Yoshimura M; Ochi Y; Miyazaki T; Shiomi K; Hachiya T
    Endocrinol Jpn; 1972 Dec; 19(6):543-8. PubMed ID: 4679232
    [No Abstract]   [Full Text] [Related]  

  • 74. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa.
    Boyd AE; Lebovitz HE; Feldman JM
    J Clin Endocrinol Metab; 1971 Nov; 33(5):829-37. PubMed ID: 5125386
    [No Abstract]   [Full Text] [Related]  

  • 75. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
    Sharpless NS; Muenter MD; Tyce GM; Owen CA
    Clin Chim Acta; 1972 Mar; 37():359-69. PubMed ID: 5022100
    [No Abstract]   [Full Text] [Related]  

  • 76. Emotional functions in short-term vs. long-term L-Dopa therapy in Parkinsonism.
    Maskin MB; Riklan M; Chabot D
    J Clin Psychol; 1973 Oct; 29(4):493-5. PubMed ID: 4148857
    [No Abstract]   [Full Text] [Related]  

  • 77. Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
    Gauthier G; Juge O; Birchler A
    Eur Neurol; 1974; 11(3):133-57. PubMed ID: 4839098
    [No Abstract]   [Full Text] [Related]  

  • 78. L-dopa and S-adenosylmethionine.
    Matthysse S; Lipinski J; Shih V
    Clin Chim Acta; 1971 Nov; 35(1):253-4. PubMed ID: 5127003
    [No Abstract]   [Full Text] [Related]  

  • 79. Reduction of catechol-O-methyl-transferases activity by chronic L-dopa therapy.
    Weiss JL; Cohn CK; Chase TN
    Nature; 1971 Nov; 234(5326):218-9. PubMed ID: 4943087
    [No Abstract]   [Full Text] [Related]  

  • 80. Effect of L-dopa on electromyograph and heart rate of parkinsonians.
    De Vito AJ; Riklan M; Misiak H
    Percept Mot Skills; 1972 Feb; 34(1):51-4. PubMed ID: 5011849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.